Anti-cd56 antibody-drug conjugates and their use in therapy
OwnerLudovic JUEN, Christine BALTUS +5inventors
InventorsLudovic JUEN, Christine BALTUS, Audrey DESGRANGES, Antoine TOUZÉ, Thibault KERVARREC, Valérie LEBLOND, Mahtab SAMIMI
Life of this patent
Estimating the term…
Abstract
The invention relates to antibody-drug conjugates and to their use in therapy, in particular for treating CD56+ cancers.
Claims21
An anti-CD56 antibody-drug conjugate (ADC) comprising an anti-CD56 antibody and a drug conjugate, wherein the ADC has one or more effective functions mediated by an Fc portion of the anti-CD56 antibody attenuated, wherein the one or more effective functions mediated by the Fc portion are selected from ADCC (Antibody-Dependent Cell-mediated Cytotoxicity) and CDC (Complement-Dependent Cytotoxicity).
An anti-CD56 antibody-drug conjugate (ADC) comprising a Fc portion, wherein said Fc portion does not carry a glycosylation.
Dependencies are inferred from the claim text.